Prospective Evaluation on Cognitive Function & Its Associated Genetic

Status Enrolling by invitation

Clinical Trial Summary

Most of the studies assessing Cannabis Use Disorder (CUD) and neurocognitive functions are cross-sectional without examining the longitudinal changes in neurocognitive function at a within-subject level with respect to the continuum of cannabis use behavior, or mainly studying on the acute cannabis effect. As for the Genome-wide Association studies, the population analyzed for addressing the underlying genetic susceptibility between neurocognitive functions and/or cannabis use or CUD were almost exclusively based on African- or European- American samples or other Caucasian subjects, and thus generalizability to Chinese or to the non-Caucasian population definitely demands more studies. With the upsweeping statistical figures of cannabis use in Hong Kong and Asia, and the substantial falls in the perceived risk and personal disapproval from using cannabis amongst young abusers, coinciding the global advocacy of de-criminalizing cannabis and the increased availability of recreational cannabis worldwide, it is reasonable to predict that there will be a further upsurge in numbers of all aged cannabis users in Hong Kong as in the other part of the world. Therefore, the SToP-C-PeCoG study proposed here as a prospective study in assessing the longer term changes in neurocognitive functions and the associated genetic risks for those repeated and active cannabis users without psychiatric co-morbidity is definitely warranted. The PeCoG study will not only provide the scientific evidence to further unveil the harmful effects on neurocognitive functions for those self-perceived "healthy" users, but also help to raise the public awareness and to improve the understandings to the long-term detrimental effects of cannabis amongst users and non-users. Furthermore, it will provide a chance to study the associated genetic risks for cannabis abusers, in particular in the Asian minority and Chinese, on CUD and poorer neurocognitive outcomes, with genetic vulnerability being generalizable to the local population in Asia. The current study hypothesises that cannabis abusers have neurocognitive function decline over time, and genetic vulnerability is associated with cannabis abusers who have poorer neurocognitive outcomes or with the severity of CUD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04373525
Study type	Observational
Source	The University of Hong Kong
Contact
Status	Enrolling by invitation
Phase
Start date	November 1, 2020
Completion date	August 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03253926` - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration	Phase 1/Phase 2
Completed	`NCT04060602` - Personalized Feedback Intervention to Reduce Risky Cannabis Use.	N/A
Completed	`NCT01212081` - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting	`NCT04988490` - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting	`NCT05188404` - Aging and Marijuana: Benefits, Effects, and Risks
Completed	`NCT03662737` - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting	`NCT05999383` - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration	Phase 2
Terminated	`NCT04436055` - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting	`NCT04374773` - Effects of Pregnancy-associated Hormones on THC Metabolism in Women	Phase 4
Completed	`NCT04316741` - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use	N/A
Recruiting	`NCT05396638` - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder	N/A
Recruiting	`NCT05309226` - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting	`NCT03859089` - Cannabis for Opioid Substitution Trial
Recruiting	`NCT05849636` - Alerta Cannabis: Evaluation of Web-based Tailored Intervention	N/A
Enrolling by invitation	`NCT05521321` - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit	N/A
Recruiting	`NCT05119244` - Environment and Lung Cancer	N/A
Recruiting	`NCT04841655` - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated	`NCT04100590` - Eye Tracking as a Biomarker of Cannabis Effects	Phase 2
Completed	`NCT05167097` - Mindsets and the Effectiveness of a Brief Intervention - Replication	N/A
Recruiting	`NCT04114903` - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users — SToP-C_PeCoG

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms